GLP-2

What is GLP-2?

Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid peptide hormone encoded within the preproglucagon gene alongside glucagon, GLP-1, and oxyntomodulin. In the intestine, prohormone convertase 1/3 (PC1/3) processes proglucagon into GLP-1, GLP-2, and oxyntomodulin — distinct from the pancreatic alpha-cell pathway, where PC2 liberates glucagon from the same precursor. GLP-2 is co-secreted with GLP-1 from enteroendocrine L-cells in response to nutrient intake, especially carbohydrate and lipid in the distal small intestine and colon. Unlike its sibling GLP-1, GLP-2 has minimal effect on insulin secretion or systemic glucose handling. Its defining physiological role is intestinotrophic — stimulating small-intestinal mucosal growth, crypt-cell proliferation, villus elongation, nutrient absorption, and epithelial barrier integrity, while also increasing mesenteric blood flow and slowing gastric emptying. Native GLP-2 has a circulating half-life of approximately 7 minutes due to rapid inactivation by dipeptidyl peptidase-4 (DPP-4), which is why the only approved GLP-2-based therapy is teduglutide, a DPP-4-resistant Gly2-substituted analog developed for short bowel syndrome.

What GLP-2 Is Investigated For

GLP-2 is discussed primarily as a physiological prototype and as the hormone behind teduglutide — not as a prescribable drug in its native form. The strongest evidence is mechanistic and clinical-translational: Daniel Drucker's group at the University of Toronto established in 1996 that GLP-2 is the proglucagon product responsible for the intestinal overgrowth seen in proglucagon-secreting tumor models, and subsequent rodent, large-animal, and human work has confirmed that GLP-2 receptor (GLP-2R) activation drives villus elongation, crypt-cell proliferation, mucosal surface area expansion, epithelial barrier tightening, and mesenteric blood flow, with minimal effect on insulin secretion. Because native GLP-2 has a minutes-scale half-life, it has not been developed as a chronic therapy; the clinically meaningful representative is teduglutide (Gattex/Revestive), FDA-approved for short bowel syndrome with intestinal failure, which delivers the same GLP-2R pharmacology with a pharmacokinetic profile compatible with once-daily injection. Emerging research investigates GLP-2 and GLP-2R agonists in neonatal necrotizing enterocolitis, pediatric intestinal failure, ischemia-reperfusion injury, inflammatory bowel disease, and radiation enteritis, but those indications are preclinical or early clinical. The honest caveats: native GLP-2 is not a prescribable drug; longer-acting GLP-2R agonists beyond teduglutide are still emerging in the pipeline; and the broader gut-health framing often applied to GLP-2 online does not match the actual clinical footprint, which is narrow and concentrated on anatomic short bowel.

History & Discovery

GLP-2 was identified in the mid-1980s as a proglucagon-derived peptide encoded just carboxyterminal to GLP-1 in the same precursor, but for about a decade it had no ascribed biological function. The breakthrough came from Daniel Drucker's laboratory at the University of Toronto. In 1996, Drucker, Patricia Brubaker, Sylvia Asa, and colleagues published in PNAS the observation that nude mice bearing subcutaneous proglucagon-producing tumors developed striking small-intestinal epithelial proliferation, and they identified GLP-2 — not glucagon, not GLP-1 — as the proglucagon product responsible. This reframed GLP-2 from orphan peptide to the first known endogenous intestinotrophic hormone. Over the following decade the Drucker, Brubaker, and Yusta groups, along with collaborators at Copenhagen (Jens Juul Holst, Bolette Hartmann), systematically characterized GLP-2's receptor (GLP-2R), its tissue distribution (gut-restricted, on subepithelial myofibroblasts and enteric neurons rather than enterocytes), the downstream paracrine mediators (IGF-1, KGF, ErbB ligands), and its rapid inactivation by dipeptidyl peptidase-4 (DPP-4). The DPP-4 insight was the critical translational hinge: native GLP-2 with its ~7-minute half-life could not be a chronic therapy, but a degradation-resistant analog might. Drucker synthesized [Gly2]GLP-2, substituting the DPP-4-susceptible alanine at position 2 with glycine, which extended in vivo half-life substantially without compromising GLP-2R activity. This molecule was licensed from the University of Toronto to 1149336 Ontario Inc. and then to NPS Pharmaceuticals, which developed it clinically as teduglutide. NPS was acquired by Shire in 2015 (and subsequently by Takeda in 2019). The FDA approved teduglutide as Gattex in December 2012 for adult short bowel syndrome dependent on parenteral support, with pediatric approval (down to age 1) added in 2019. Outside the US the drug is marketed as Revestive. Teduglutide remains the only marketed product built on GLP-2 biology, though longer-acting GLP-2R agonists (glepaglutide, apraglutide) are in later-stage development for the same indication.

How It Works

GLP-2 is a gut hormone released after meals that tells the intestinal lining to grow and maintain itself. It doesn't act on the gut's absorptive cells directly — it signals to support cells underneath them, which release growth factors that do the work. The drug teduglutide is basically a version of GLP-2 engineered to last long enough to be useful as a once-daily injection.

GLP-2 is a 33-amino-acid peptide cleaved from preproglucagon by prohormone convertase 1/3 (PC1/3) in intestinal L-cells, which also produce GLP-1 and oxyntomodulin from the same precursor. (The pancreatic alpha cell, by contrast, uses PC2 to generate glucagon from the same gene product — the classic example of tissue-specific post-translational processing.) GLP-2 is secreted postprandially in proportion to nutrient load, with strong stimuli from carbohydrate and lipid reaching the distal small intestine and colon. GLP-2 acts on a single G-protein-coupled receptor (GLP-2R) that is expressed predominantly within the gastrointestinal tract. Critically, GLP-2R is not expressed by enterocytes directly. Immunolocalization and in situ hybridization studies have identified GLP-2R on subepithelial myofibroblasts, on subsets of enteric neurons (including VIP-expressing and nNOS-expressing populations), and on certain enteroendocrine cells. The intestinotrophic effect of GLP-2 is therefore paracrine and indirect: GLP-2R activation on subepithelial myofibroblasts drives the release of insulin-like growth factor-1 (IGF-1), keratinocyte growth factor (KGF, primarily relevant for colonic growth), and ErbB-family ligands (primarily relevant for small-intestinal growth), which in turn bind their cognate receptors on crypt epithelial cells to stimulate proliferation, suppress apoptosis, and expand villus height and crypt depth. The intestinal epithelial IGF-1 receptor is required for the crypt-cell proliferative response to GLP-2 — targeted deletion abolishes it. GLP-2R activation on enteric neurons mediates additional effects, including increased mesenteric blood flow (partly via nNOS and VIP release), suppression of gastric emptying, and modulation of mucosal chloride secretion. These neural effects contribute to the overall absorptive phenotype that makes GLP-2 and its analogs clinically interesting for intestinal failure. Native GLP-2 carries an alanine at position 2 and is a preferred substrate for dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal dipeptide to generate inactive GLP-2(3-33). This gives native human GLP-2 a circulating half-life of approximately 7 minutes. Drucker and colleagues exploited this by synthesizing a Gly2-substituted analog ([Gly2]GLP-2) that resists DPP-4 cleavage and extends half-life to roughly 2 hours; that analog became teduglutide, approved by the FDA in 2012 as Gattex and marketed internationally as Revestive.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about GLP-2:

• 01Longer-acting GLP-2R agonists beyond teduglutide — glepaglutide and apraglutide are advancing into late-stage human trials (a 2026 Clin Nutr ESPEN report describes 24-week glepaglutide Phase III microbiome data, and a separate 2026 Phase II reports early apraglutide-induced microbiota shifts), but comparative long-term outcomes versus teduglutide on parenteral-nutrition independence, hospitalization rates, and adult-population safety are not yet established.
• 02Role of GLP-2R agonism in neonatal necrotizing enterocolitis (NEC) — endogenous GLP-2 production is reduced in infants who lose distal small bowel, but prospective trials of GLP-2R agonism for NEC prevention or treatment are limited.
• 03Radiation enteritis and chemotherapy-induced mucositis — strong preclinical rationale for GLP-2R agonism, but human trials have been small and indications are not established.
• 04Inflammatory bowel disease — GLP-2 shows anti-inflammatory and mucosal-healing effects in animal models and small human studies, but teduglutide failed to meet primary endpoints in Crohn's disease trials and the therapeutic niche for GLP-2R agonism in IBD remains undefined.
• 05Long-term neoplasia risk — chronic intestinotrophic stimulation raises theoretical concern for colorectal and small-bowel neoplasia; postmarketing registries for teduglutide are the primary source of long-term human data, and those data are still maturing.
• 06Endogenous GLP-2 as a biomarker — circulating GLP-2 levels after intestinal resection, in IBD, and in enteropathies have been explored but are not established clinical biomarkers.
• 07Tissue-specific proglucagon processing — the regulatory inputs controlling the L-cell PC1/3 versus alpha-cell PC2 decision are incompletely defined, and pharmacologic manipulation of this axis is an open frontier.
• 08CNS frontier — emerging preclinical data (Peptides 2026) describes neuroprotective effects of GLP-2 and a GLP-2/GIP dual-agonist in an MPTP mouse model of Parkinson's disease, raising the possibility of central nervous system indications for GLP-2R agonism distinct from the gut-restricted clinical framing; receptor distribution, blood-brain-barrier penetration, and translational relevance remain to be established.
• 09Short-fragment / truncated GLP-2 analogs — a 2026 Peptides report describes an ultra-short [Gly²]-GLP-2(1-5) pentapeptide showing intestinal-barrier protection in IBD models, suggesting the minimum bioactive sequence may be substantially shorter than the full 33-residue peptide; whether such fragments retain the paracrine IGF-1/KGF/ErbB cascade or work through a different mechanism is unresolved.

Forms & Administration

Native GLP-2 has no approved clinical formulation and has been used only in research settings — intravenous infusion or short-course subcutaneous injection in small human studies. The clinically relevant pharmaceutical expression of GLP-2R pharmacology is teduglutide (Gattex/Revestive), a lyophilized peptide for once-daily subcutaneous injection, prescribed for short bowel syndrome with intestinal failure. Patients interested in the biology of GLP-2 as a therapy should refer to the teduglutide entry; there is no legitimate clinical pathway for native GLP-2 administration.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions